We are live on ! Find out more
STRO icon

Sutro Biopharma

134 hedge funds and large institutions have $819M invested in Sutro Biopharma in 2020 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 45 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

369% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 13

200% more funds holding in top 10

Funds holding in top 10: 26 (+4)

169% more capital invested

Capital invested by funds: $304M → $819M (+$515M)

150% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 18

96% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $763K

56% more funds holding

Funds holding: 86134 (+48)

0.14% more ownership

Funds ownership: 8.51%8.66% (+0.14%)

Holders
134
Holders Change
+48
Holders Change %
+55.81%
% of All Funds
2.37%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.11%
New
61
Increased
45
Reduced
18
Closed
13
Calls
$1.5M
Puts
$763K
Net Calls
+$732K
Net Calls Change
+$732K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$59M +$11.1M +67,037 +33%
EAM
2
Eventide Asset Management
Massachusetts
$51.5M +$6.37M +38,500 +19%
Franklin Resources
3
Franklin Resources
California
$48.3M +$36.9M +222,692 New
RCM
4
RA Capital Management
Massachusetts
$46M
Vanguard Group
5
Vanguard Group
Pennsylvania
$41.8M +$10.3M +62,381 +48%
BI
6
BVF Inc
California
$40.3M -$20.4M -123,304 -40%
SHI
7
SV Health Investors
Massachusetts
$39.6M
Baillie Gifford & Co
8
Baillie Gifford & Co
United Kingdom
$36.8M
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$30.6M +$6.6M +39,881 +39%
Citadel Advisors
10
Citadel Advisors
Florida
$28.1M +$1.21M +7,287 +6%
Holocene Advisors
11
Holocene Advisors
New York
$23.2M +$17.7M +106,726 New
SCM
12
Suvretta Capital Management
New York
$22.5M -$2.23M -13,476 -12%
FM
13
Frazier Management
Washington
$21.7M +$16.6M +100,142 New
FLAM
14
First Light Asset Management
Minnesota
$18M +$13.7M +82,710 New
Fidelity International
15
Fidelity International
Bermuda
$16.2M +$6.48M +39,156 +111%
TCM
16
Tekla Capital Management
Massachusetts
$15.3M +$1.01M +6,125 +10%
APM
17
Avidity Partners Management
Texas
$13.6M +$10.4M +62,600 New
IC
18
Ikarian Capital
Texas
$13.4M +$2.11M +12,736 +26%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$11.8M +$3.38M +20,440 +60%
Adage Capital Partners
20
Adage Capital Partners
Massachusetts
$10.3M -$4.14M -25,000 -34%
State Street
21
State Street
Massachusetts
$9.83M +$2.13M +12,877 +40%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$9.09M +$1.62M +9,804 +31%
CS
23
Candriam SCA
Luxembourg
$7.99M +$6.09M +36,811 New
MWNA
24
Marshall Wace North America
New York
$7.77M +$5.93M +35,799 New
O
25
OrbiMed
New York
$7.6M +$5.79M +35,000 New

STRO Hedge Fund Activity: Q4 2020 in Review

134 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q4 2020, worth a combined $819M — up 169% from $304M a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new STRO positions and 13 closed out — a net gain of 48 holders — while 45 added to existing stakes and 18 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $36.9M. The largest seller was EcoR1 Capital, cutting an estimated $50M.

  • 134 institutional investors held Sutro Biopharma (STRO) as of Q4 2020, up from 86 in Q3 2020.
  • Funds reported $819M of Sutro Biopharma stock for Q4 2020, up 169% quarter-over-quarter.
  • 61 funds opened new Sutro Biopharma positions in Q4 2020 and 13 closed out, a net change of +48 holders.
  • The largest Sutro Biopharma buyer in Q4 2020 was Franklin Resources, an estimated $36.9M added.
  • The largest Sutro Biopharma seller in Q4 2020 was EcoR1 Capital, an estimated $50M sold.

Based on aggregated 13F filings for Q4 2020.